Anti-Human Hepsin (Clone 3H10.1) – Purified No Carrier Protein

Clone 3H10.1 is most commonly used in vivo in mice as an anti-human hepsin monoclonal antibody, primarily for cancer research applications involving human hepsin-expressing tumor xenografts.

Key applications include:

• Evaluating hepsin function and expression: Clone 3H10.1 specifically binds to full-length, native human hepsin—a serine protease implicated in cancer progression, especially prostate and ovarian cancers.
• Testing anti-tumor activity: In mouse models, 3H10.1 is used to study the effects of inhibiting hepsin on tumor growth, invasion, and metastasis. Anti-hepsin antibodies such as 3H10.1 have been shown to inhibit the invasion of human cancer cells in vivo.
• Preclinical immuno-oncology studies**: Researchers use 3H10.1 to characterize hepsin as a potential diagnostic marker and therapeutic target in experimental mouse models of human cancer.

Important supporting details:

• 3H10.1 does not cross-react with mouse hepsin, meaning it is used specifically in chimeric or xenograft models where mice bear human-derived tumors or tissue express human hepsin.
• Multiple suppliers offer highly purified, low-endotoxin versions of 3H10.1, explicitly marketed for in vivo use to minimize immunogenicity and experimental variability in mouse studies.
• Other research areas include cell biology, mechanistic studies of serine protease activity, and investigations into the regulation of epithelial cell function.

There is no evidence in search results that clone 3H10.1 is used for PD-1/PD-L1 blockade or general immunomodulation in mice; those studies commonly use different clones (such as RMP1-14, J43, or 29F.1A12).

In summary, clone 3H10.1 is a specialized tool for in vivo studies of human hepsin biology in mice, focused on modeling and potentially targeting cancer progression driven by human hepsin expression.

Commonly used antibodies or proteins co-applied with 3H10.1 (most often referred to as anti-phospho-Histone H3 (Ser10)) in the literature include antibodies targeting other histone modifications, cell cycle markers, and DNA damage or mitosis regulators.

Key proteins and antibodies frequently used with 3H10.1:

• Total Histone H3 antibody: Detects overall levels of Histone H3 to normalize or contrast with phospho-specific detection.
• Anti-phospho-Histone H3 (Ser28): Used to examine distinct phosphorylation events on Histone H3 during mitosis.
• Cyclin B1/B2 antibodies: Markers of specific cell cycle phases, especially mitosis.
• Aurora kinase A/B antibodies: Study of histone H3 phosphorylation is closely linked to Aurora kinase activity during mitosis.
• α-Tubulin or β-Tubulin antibodies: Microtubule markers for identifying mitotic figures and cell structure.
• Ki-67 antibody: Proliferation marker, often co-stained with pH3(S10) to assess cell proliferation versus mitosis.
• Cleaved Caspase-3 or PARP antibodies: Detection of apoptosis in conjunction with mitotic markers.

Typical combinations in immunofluorescence or Western blot:

• Anti-pH3 (Ser10) (clone 3H10.1) with total H3, Cyclin B1, Ki-67
• Anti-pH3 (Ser10) with α-Tubulin or anti-centromere antibodies in mitosis studies
• Anti-pH3 (Ser10) with Aurora kinase B and DAPI for chromosome and mitotic spindle visualization

These pairings allow researchers to:

• Distinguish mitotic cells from non-mitotic or apoptotic cells
• Quantify proliferative or mitotic index in tissue sections or cell cultures
• Dissect the relationship between histone phosphorylation, cell cycle progression, and regulatory kinases

References for anti-phospho-Histone H3 (Ser10) antibody (3H10.1) emphasize its use in combination with such cell cycle and mitosis-related markers for a comprehensive understanding of cell division and chromatin regulation.

If you meant a different "3H10.1" (in, e.g., immunology or different field), or have a specific application in mind, please clarify for a more tailored answer.

Clone 3H10.1 is most frequently cited in the scientific literature as a monoclonal antibody targeting human hepsin, a type II transmembrane serine protease that has been implicated as a marker in several cancers, most notably prostate cancer.

Key findings from major citations include:

• Specificity: Clone 3H10.1 (sometimes referred to as 3H10.1.2) is highly specific for full-length native hepsin expressed on human cell surfaces, as well as the recombinant soluble form.
• Epitope recognition: 3H10.1 recognizes an epitope on hepsin that is also targeted by other clones (3H1.1.1 and 1F2.1.1), with mutual inhibition of binding among these clones. In contrast, some clones like 2D5.1.9 bind different, non-competing epitopes.
• Hepsin as a cancer biomarker: The over-expression of hepsin (the antigen recognized by clone 3H10.1) is strongly correlated with the progression and metastasis of prostate cancer, making anti-hepsin antibodies derived from clone 3H10.1 important for research in cancer diagnosis and possibly therapy.
• Functional studies: Antibodies to hepsin, including those from clone 3H10.1, have been shown to inhibit the invasion of human prostate cancer cells, highlighting their potential therapeutic relevance in oncology.
• Broader applications: Hepsin is also implicated in activating blood clotting proteins (such as factor VII, IX, and XII), and pathways relevant to cancer biology (e.g., via pro-HGF and uPA), expanding the utility of clone 3H10.1 antibodies in both basic research and translational cancer studies.

Major publications cited regarding clone 3H10.1:

• Wu Q. & Parry G. (2007): This paper (Front Biosci 12: 5052-9) is often referenced for characterizing hepsin and its role in cancer, along with functional analysis using anti-hepsin antibodies.
• Kirchhofer D. et al. (2006): Published in J Biol Chem. 281(41):30439-46, also cited for studies on hepsin’s molecular function and antibody interactions.

In summary, clone 3H10.1 is significant for its utility in detecting hepsin—a protease overexpressed in prostate cancer and potentially other malignancies—and has provided insight into hepsin’s function and cancer relevance, as well as being used to investigate antibody-based inhibition of cancer cell invasion.

Dosing regimens for clone 3H10.1 in mouse models are not documented in the provided search results, nor in widely available antibody dosing databases or supplier literature. The available data references clone 3H10 (anti-phospho-Histone H3 Ser10) for immunohistochemistry or flow cytometry applications, but not for in vivo dosing, and there is no evidence that 3H10.1 is typically administered to live mice in a dosing regimen.

Key context and supporting details:

• Clone 3H10.1 does not appear in standard in vivo antibody dosing guides, such as those that list commonly used antibodies in mouse cancer or immunology models.
• Product sheets and supplier data for the closely named clone 3H10 only describe its use in fixed cell or tissue assays (e.g., immunofluorescence, immunohistochemistry), not for administration into living animals.
• Antibody dosing regimens for in vivo studies in mice (such as for immune depletion, checkpoint blockade, or treatment models) usually specify dose (e.g., μg per mouse), frequency, route (usually intraperitoneal), and experimental context. No such parameters are provided for 3H10.1 in the results or typical antibody dosing guides.

If clone 3H10.1 is being considered for in vivo dosing in mice, dosing regimens must be determined empirically or by analogy to structurally and functionally similar antibodies, extrapolating from their pharmacokinetics and effects, often in consultation with the antibody supplier and specialist literature.

If you require a regimen for in vitro or ex vivo use (e.g., immunofluorescence, Western blot, immunohistochemistry), standard working concentrations (such as 0.2-1 μg/mL) are available for clone 3H10 but should not be extrapolated for in vivo dosing.

If you have a specific indication or context for 3H10.1 use in mice, or if this is a custom/laboratory-generated clone, please clarify or consult the originating laboratory for empirically determined dosing information.